

The iQ3Corp IPO Share Offer is now open.

iQ3Corp Limited is the world's first dedicated corporate finance and advisory firm that provides capital raising and corporate advisory services to listed and unlisted companies in the Life Sciences industry.

iQ3Corp understands the needs of early stage Biotech and we work with scientists developing life-changing technology. iQ3Corp is committed to supporting life science companies throughout the entire drug development life cycle, taking private companies to the world via listed global markets.

iQ3Corp provides corporate finance and advisory services to life science companies and advise them on their most critical financial decisions, including capital raisings, recapitalisations and restructures, M&A and investor relations strategy.

iQ3Corp is intend to raise \$4.09m - \$4.40m in the Offer. The Prospectus can be downloaded at www.iq3corp.com.

If you have any queries about the Offer, please visit <http://www.iq3corp.com/> or contact our Investor Relations team at investor.relations@iq3corp.com or on +61 2 8239 5400.

DISCLAIMER:

The offer of shares in iQ3Corp Limited (**iQ3Corp**) by iQ3Corp Limited (**iQ3Corp Share Offer** or **Offer**) is only made through the Replacement Prospectus (**Prospectus**), which you should consider in deciding whether to apply for shares. To apply, you need to complete the application form in or with the Prospectus, and made available after the exposure period. A copy of the Prospectus may be obtained by visiting www.iq3corp.com or calling +61 2 8239 5400. Nothing in this document constitutes an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. The shares referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933 (the **U.S. Securities Act**) or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or an exemption from registration requirements. Capitalised terms in this email have the meaning given to them in the Prospectus lodged with ASIC on 23 February 2015.